507 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Mitchell Mcleod Pugh & Williams Inc.

Mitchell Mcleod Pugh & Williams Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 507 shares of the pharmaceutical company’s stock, valued at approximately $204,000.

Other institutional investors also recently modified their holdings of the company. Northwest Investment Counselors LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $27,000. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $33,000. Finally, Truvestments Capital LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $35,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.2 %

Shares of Vertex Pharmaceuticals stock opened at $422.00 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a fifty day moving average of $440.94 and a 200 day moving average of $466.06.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.67 EPS. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Barclays decreased their price objective on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a report on Friday, December 20th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Monday, January 13th. Royal Bank of Canada upped their target price on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Finally, Truist Financial cut their target price on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.